EUVIMEDOdkrijte EUVIMED
Übersichtsarbeit

Beyond Antibodies: Glypican‐3‐Targeting Peptides for Precision Hepatocellular Carcinoma Theranostics

Narendra Raju Nagpure iD, Nitesh Mani Tripathi iD, Neelam Verma iD, Anupam Bandyopadhyay iD

Journal of Peptide Science · 2026

DOI: 10.1002/psc.70134 ↗

At a glance

Übersichtsarbeit in Journal of Peptide Science, 2026. Written by Narendra Raju Nagpure and 3 co-authors. Institution: Biomimetic Peptide Engineering Laboratory, Department of Chemistry, Indian Institute of Technology Ropar, Rupnagar, Punjab, India. Major MEDLINE topics: Glypicans, Carcinoma, Hepatocellular, Liver Neoplasms, Peptides. 51 references.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Glypican‐3 (GPC‐3) is a cell‐surface glycoprotein, highly expressed in hepatocellular carcinoma (HCC) but largely absent in normal adult liver tissues, making it a clinically compelling biomarker and therapeutic target. Although monoclonal antibodies and antibody‐drug conjugates have proven to be GPC‐3‐targeted therapies, their large molecular size, slow pharmacokinetics, and potential immunogenicity limit their diagnostic applications. Peptide ligands offer an attractive alternative owing to their low molecular weight, rapid tumor penetration, favorable clearance profiles, synthetic accessibility, and ease of chemical modification. This topical review highlights the development of linear and cyclic GPC‐3‐binding peptides over the past two decades, developed primarily via phage display, rational optimization, and structure‐guided approaches, enabling PET, SPECT, and fluorescence imaging of HCC in preclinical models. Recent refinements, including albumin‐binding modifications and cyclization strategies, have improved tumor‐to‐liver contrast and in vivo stability. This review summarizes the biological significance of GPC‐3, compares peptides and peptide probes as targeting modalities, and critically analyzes recent advances in linear and cyclic peptide‐based GPC‐3 imaging probes. We also emphasized the importance, current challenges, and future opportunities in AI/ML‐based design of peptide ligands for HCC theranostics.

Subjects

MeSH terms (MEDLINE)

GlypicansCarcinoma, HepatocellularLiver NeoplasmsPeptidesTheranostic NanomedicineHumansAnimalsPrecision Medicine

Author keywords

cancer imagingglypican‐3 (GPC‐3)hepatocellular carcinomapeptidetheranostics

Substances

GlypicansGPC3 protein, humanPeptides

Authors and institutions

  • Biomimetic Peptide Engineering Laboratory, Department of Chemistry, Indian Institute of Technology Ropar, Rupnagar, Punjab, India.

ORCID profiles: Narendra Raju Nagpure, Nitesh Mani Tripathi, Neelam Verma, Anupam Bandyopadhyay

Cite

APA

Nagpure, N. R., Tripathi, N. M., Verma, N., & Bandyopadhyay, A. (2026). Beyond Antibodies: Glypican‐3‐Targeting Peptides for Precision Hepatocellular Carcinoma Theranostics. Journal of Peptide Science. https://doi.org/10.1002/psc.70134

Vancouver

Nagpure NR, Tripathi NM, Verma N, Bandyopadhyay A. Beyond Antibodies: Glypican‐3‐Targeting Peptides for Precision Hepatocellular Carcinoma Theranostics. Journal of Peptide Science. 2026. doi:10.1002/psc.70134

BibTeX
@article{Nagpure2026,
  author = {Nagpure, Narendra Raju and Tripathi, Nitesh Mani and Verma, Neelam and Bandyopadhyay, Anupam},
  title = {Beyond Antibodies: Glypican‐3‐Targeting Peptides for Precision Hepatocellular Carcinoma Theranostics},
  journal = {Journal of Peptide Science},
  year = {2026},
  doi = {10.1002/psc.70134}
}
Start for free →